• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA's Vitamin D Supplement Shines Bright with ConsumerLab.com Seal of Approval--Setting the Standard for Product Quality

    10/16/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, is bringing a little more sunshine to wellness. Its top-rated Vitamin D supplement has officially earned the prestigious ConsumerLab.com Seal of Approval—a recognition reserved for products that deliver on purity, potency, and scientific precision. With approximately 42% of adults in the United States considered vitamin D deficient, having a vitamin D supplement on the market you can trust makes all the difference.

    USANA's Vitamin D supplements earns a ConsumerLab.com Seal of Approval

    "This isn't just a win for our product—it's a win for consumers who deserve the very best," said Brent Neidig, USANA's Chief Commercial Officer. "We're proud to offer a supplement that not only meets expectations but inspires confidence in every tablet. The ConsumerLab.com Seal of Approval is more than a certification—it's a trusted endorsement that reflects our dedication to transparency, quality, and precision."

    To earn the Seal of Approval, USANA's Vitamin D supplement was subjected to comprehensive testing for potency, purity, and label accuracy. The product was required to deliver 100% of the claimed amounts of vitamin D3 and vitamin K and demonstrate proper disintegration and bioavailability—benchmarks that align with USANA's own uncompromising internal standards.

    All the Sunshine You Need in One Tablet

    USANA's maximum-strength Vitamin D is your daily dose of sunshine in a tablet. Whether it's cloudy skies or cozy winter days, this powerhouse supplement can help provide some amazing benefits. USANA's Vitamin D supplement:

    • Helps with development and maintenance of bones and teeth*
    • Aids in the absorption and use of calcium and phosphorus*
    • Provides 50 mcg (2000 IU) of vitamin D per tablet—more than four times the amount of the current recommendation

    "At USANA, we don't just meet standards—we redefine them," said Dr. Kathryn Armstrong, USANA's chief scientific officer. "With 2000 IU of vitamin D3 in every tablet, this formula is built on science to support bone strength, immune defense, and nutrient absorption. Trust in your supplements has to be earned—and we earn it with every dose."

    The approval from ConsumerLab.com is the latest in a long line of third-party validations that reflect USANA's role as an industry leader in evidence-based nutritional science.

    USANA continues to invest in cutting-edge research, state-of-the-art manufacturing, and gold-standard testing protocols—ensuring that every product not only meets expectations but sets a new bar for excellence.

    Experience the power of premium nutrition. Visit USANA.com to learn more about how USANA's award-winning products bring science and wellness together.

    *These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    About USANA

    USANA (NYSE:USNA) has been providing premium-quality nutrition and lifestyle products for more than 30 years. From its award-winning supplements manufactured in its FDA-registered facility to its cutting-edge Celavive skincare and healthy living products, USANA is committed to empowering people to live healthier, more vibrant lives.

    Discover the future of nutrition at USANA.com or explore the science at AskTheScientists.com.

    Media Contact:

    (801) 954-7645

    media(at)USANAinc(dot)com

    USANA Logo (PRNewsfoto/USANA)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/usanas-vitamin-d-supplement-shines-bright-with-consumerlabcom-seal-of-approvalsetting-the-standard-for-product-quality-302585740.html

    SOURCE USANA

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INFORMATION OFFICER Benedict Peter converted options into 2,788 shares and covered exercise/tax liability with 967 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:56:37 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF OPERATING OFFICER Noot Walter covered exercise/tax liability with 4,160 shares and converted options into 9,138 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:55:30 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF COMMERCIAL OFFICER Neidig Brent converted options into 7,310 shares and covered exercise/tax liability with 3,551 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:54:18 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps

    SALT LAKE CITY, Feb. 2, 2026 /PRNewswire/ -- As organizations face rapid market disruption and evolving leadership demands, Feb. 2 marks Self-Renewal Day, a pivotal time for business leaders to recalibrate strategies and personal development. "Growth does not happen by accident; it happens by choice," said  Kevin Guest, Executive Chairman & CEO at USANA Health Sciences (NYSE:USNA). "Self-Renewal Day is designed to prompt people to evaluate their lives, challenge complacency, and take deliberate steps toward personal and professional renewal." This annual observance is a critic

    2/2/26 7:05:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Baystreet.ca News Commentary  VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE:PM), Celsius Holdings (NASDAQ:CELH), USANA Health Sciences (NYSE:USNA), and Medifast (NYSE:MED

    1/19/26 12:10:00 PM ET
    $CELH
    $MED
    $PM
    Beverages (Production/Distribution)
    Consumer Staples
    Packaged Foods
    Medicinal Chemicals and Botanical Products

    $USNA
    SEC Filings

    View All

    Amendment: USANA Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    2/11/26 4:51:10 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    1/21/26 1:21:12 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/12/26 6:29:11 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care